Overview

Detailed Summary

Nephrocare Health Services Limited (NephroPlus) operates Asia’s largest dialysis network, providing end‑to‑end dialysis care across formats (standalone clinics, captive hospital units, PPPs, home dialysis, dialysis on wheels) with 521 global clinics across India, Philippines, Uzbekistan, Nepal and KSA and over 36,000 guests served as of 9M FY26.
The company reported strong 9M FY26 results with revenue of ₹733.2 crore, adjusted EBITDA of ₹175.4 crore (23.9% margin) and adjusted PAT of ₹85.9 crore, reflecting a high operating leverage model enabled by scale, disciplined consumables procurement, and rapid international mix shift driving higher RPTs and ROCE expansion.
NephroPlus has a demonstrable international playbook: winning a large Uzbekistan PPP, establishing the world’s largest dialysis centre in Tashkent, becoming the third largest dialysis network in Philippines, and entering KSA via a JV, driving international revenue to 41% of 9M FY26 consolidated revenue and materially lifting blended realizations.
The business model is asset‑light and replicable with ~52% clinics under revenue‑sharing, strong hospital partnerships and a disciplined M&A integration engine; management targets 15%–20% revenue CAGR over the next 3–4 years, prioritizing ROCE‑accretive opportunities and cash conversion while selectively investing in new geographies and technology.

Sector: Healthcare
Industry: Hospitals / Medical Services
Market Cap: 5,622 Cr
Volatility: Low Risk
P/E Ratio: 70.4
Industry P/E: 60.4
PEG Ratio: 0.8
P/B Ratio: 5.2
52W High: 619.05
52W Low: 445.00

Sales CAGR

1Y: 33.50%
3Y: —
5Y: —
10Y: —

Profit CAGR

1Y: 91.00%
3Y: —
5Y: —
10Y: —

ROE

TTM: 8.26%
3Y: 6.52%
5Y: 3.41%
10Y: —

ROCE

TTM: 14.94%
3Y: 9.58%
5Y: 6.23%
10Y: —

Technicals

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
HCG	556.55	8,309 Cr	418.39	6.18	0.00	3.84	7.73	0.71
JLHL	1271.80	8,274 Cr	44.21	5.70	0.08	13.66	15.60	9.33
YATHARTH	646.75	6,232 Cr	36.50	3.69	0.00	9.03	11.86	8.89
KOVAI	5289.00	5,764 Cr	99.81	4.84	0.19	19.21	21.31	12.30
NEPHROPLUS	564.00	5,622 Cr	70.41	5.18	0.00	8.26	14.94	0.00
ARTEMISMED	233.85	3,677 Cr	42.34	3.21	0.17	10.76	13.34	6.76
INDRAMEDCO	395.25	3,655 Cr	19.81	5.55	1.13	26.54	34.84	19.17

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Dec 2024	Sep 2025	Dec 2025
Sales	197	246	260
Expenses	153	182	199
Operating Profit	44	64	61
OPM %	22.35	26.02	23.43
Other Income	5.37	3.89	3.32
Interest	4.85	45	5.96
Depreciation	18	23	22
Profit Before Tax	26	-0.62	36
Tax %	23.94	-1,427.42	11.33
Net Profit	20	-9.47	32
EPS in Rs	—	—	3.35

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2023	Mar 2024	Mar 2025
Sales	437	566	756
Expenses	389	465	589
Operating Profit	49	101	167
OPM %	11.11	17.82	22.05
Other Income	5.96	8.57	14
Interest	16	20	21
Depreciation	47	56	72
Profit Before Tax	-8.59	33	87
Tax %	-37.23	-5.95	23.26
Net Profit	-12	35	67
EPS in Rs	—	—	—
Dividend Payout %	0.00	0.00	0.00

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2023	Mar 2024	Mar 2025
Equity Capital	1.74	1.75	1.77
Reserves	387	412	582
Borrowings	214	268	258
Other Liabilities	64	124	155
Total Liabilities	666	806	996
Fixed Assets	239	356	396
CWIP	34	0.69	5.84
Investments	0.00	0.00	51
Other Assets	393	450	544
Total Assets	666	806	996

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	11	72	135
Cash from Investing Activity	-78	-51	-125
Cash from Financing Activity	60	27	54
Net Cash Flow	-6.97	48	65

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jul 2025	Dec 2025
Promoters	79.06%	63.85%
FIIs	0.00%	3.59%
DIIs	20.95%	8.68%
Public	0.00%	23.88%
Total Shareholders	65	2,12,979

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Upgrade

Projection

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q3 FY26

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Nephrocare Health Services Ltd

Nephrocare Health Services Ltd (NEPHROPLUS) is currently trading at 564.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Nephrocare Health Services Limited (NephroPlus) operates Asia’s largest dialysis network, providing end‑to‑end dialysis care across formats (standalone clinics, captive hospital units, PPPs, home dialysis, dialysis on wheels) with 521 global clinics across India, Philippines, Uzbekistan, Nepal and KSA and over 36,000 guests served as of 9M FY26. The company reported strong 9M FY26 results with revenue of ₹733.2 crore, adjusted EBITDA of ₹175.4 crore (23.9% margin) and adjusted PAT of ₹85.9 crore, reflecting a high operating leverage model enabled by scale, disciplined consumables procurement, and rapid international mix shift driving higher RPTs and ROCE expansion. NephroPlus has a demonstrable international playbook: winning a large Uzbekistan PPP, establishing the world’s largest dialysis centre in Tashkent, becoming the third largest dialysis network in Philippines, and entering KSA via a JV, driving international revenue to 41% of 9M FY26 consolidated revenue and materially lifting blended realizations. The business model is asset‑light and replicable with ~52% clinics under revenue‑sharing, strong hospital partnerships and a disciplined M&A integration engine; management targets 15%–20% revenue CAGR over the next 3–4 years, prioritizing ROCE‑accretive opportunities and cash conversion while selectively investing in new geographies and technology.

Over the past 52 weeks, Nephrocare Health Services Ltd has traded between a low of ₹445.00 and a high of ₹619.05. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Nephrocare Health Services Ltd has a market capitalization of approximately 5,621.59. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Nephrocare Health Services Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 70.41 and operates in the Healthcare sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 5,621.59 Cr, Nephrocare Health Services Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Nephrocare Health Services Ltd operates in the Healthcare sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Nephrocare Health Services Ltd is 70.41. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Nephrocare Health Services Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Oscillators

Neutral

Overall

Neutral

Moving Averages

Bearish

Overall

Neutral

Forecasts

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Unlock Premium Features

Upgrade

Projection

Documents

Actions

Announcements

AI Mode

Ask AI

Frequently Asked Questions about Nephrocare Health Services Ltd

What is Nephrocare Health Services Ltd share price today?

What does Nephrocare Health Services Ltd do?

What is the 52-week high and low of Nephrocare Health Services Ltd?

What is the market capitalization of Nephrocare Health Services Ltd?

Should I consider investing in Nephrocare Health Services Ltd stock?

Is Nephrocare Health Services Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Nephrocare Health Services Ltd belong to and why does it matter?

What is the PE ratio of Nephrocare Health Services Ltd?

Utility

Company

Overview

Financial Ratios

Forecasts

Shareholdings

Shareholding History

Market Transactions

Unlock Premium Features

Upgrade

Projection

Documents

Financial Statements

AI Powered Summary

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Frequently Asked Questions about Nephrocare Health Services Ltd

What is Nephrocare Health Services Ltd share price today?

What does Nephrocare Health Services Ltd do?

What is the 52-week high and low of Nephrocare Health Services Ltd?

What is the market capitalization of Nephrocare Health Services Ltd?

Should I consider investing in Nephrocare Health Services Ltd stock?

Is Nephrocare Health Services Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Nephrocare Health Services Ltd belong to and why does it matter?

What is the PE ratio of Nephrocare Health Services Ltd?

Investment Checklist

Announcements

Peers

Price Chart Comparison